PSNL: Rega marang dodolan Personalis Corp
The price-to-sales ratio helps evaluate the efficiency of the NeXT platform in decoding tumors for vaccine development for Personalis, Inc. (PSNL). The asset's dynamics are driven by demand for personalized medicine and FDA approvals. The B2B segment ensures full customer retention within the diagnostics ecosystem. This chart allows for the filtering of short-term spikes, while the metric has reached the level of 21.30, confirming market recognition of the management quality at Personalis, Inc. (PSNL).
Rincian metrik lan analitis perusahaan Personalis Corp (PSNL)
- rega saham lan prakiraan rega para ahli:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Utang marang Modal Personalis, Inc.|PSNL - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Personalis Genomics|PSNL - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Personalis Corp|PSNL - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Personalis|Koefisien jangkoan perantara personalis.com
- informasi bathi lan kelipatan valuasi:
PSNL - Bathi resik perusahaan|Prakiraan bathi perusahaan Personalis, Inc.|PSNL - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Personalis Inc|PSNL - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Personalis Corp|PSNL - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Personalis|PSNL - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan personalis.com|PSNL - Wutah bathi resik saben saham ing taun iki|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Personalis, Inc.
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:PSNL personalis.com
The assessment of the margin of safety for Personalis, Inc. (PSNL) is based on the P/S ratio, which determines the market value of one dollar of revenue, allowing for the identification of the asset's overvaluation relative to its actual sales. By analyzing historical P/S levels, an investor can compare market expectations with business resilience, which is supported by diversification between supporting pharma behemoths and hospital diagnostics within the precision oncology sector.
Pesaing Personalis, Inc.
ONC: Rasio rega marang dodolan|Multiplikator P/S HALO (Halozyme)|Revolution Medicines Inc (RVMD) - Rega marang dodolan|AAPG - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CGON (CG Oncology Therapeutics)|UroGen Pharma Ltd. (URGN) - Rasio rega marang pendapatan|BCAX - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Erasca|Rega marang dodolan Delcath Systems Inc DCTH|Rasio rega marang pendapatan YmAbs (YMAB)|Aura Corp - Rasio kapitalisasi marang pendapatan|Multiplikator P/S CADL (Candel Therapeutics, Inc.)|Multiplikator P/S accuray.com ARAY|SLS - Rasio rega marang pendapatan|ACTU: Rasio rega marang pendapatan|CTOR: Multiplikator P/S|HURA - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Protara Therapeutics|fatetherapeutics.com (FATE) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CSBR (Champions Oncology, Inc.)|Koefisien rega marang pendapatan XBiotech Inc (XBIT)|CVM - Rasio rega marang pendapatan|OSTX (ostherapies.com) - Rasio kapitalisasi marang pendapatan|RADX: Multiplikator P/S|Kapitalisasi marang pendapatan Artiva Biotherapeutics|Kapitalisasi marang pendapatan ANL|Veru Corporation (VERU) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Tempest Therapeutics (TPST)|XLO: Rasio rega marang dodolan|Rasio rega marang pendapatan Renovaro RENB|Koefisien rega marang pendapatan Mural Oncology PLC (MURA)|KAPA - Rasio rega marang pendapatan|OKUR (OnKure Therapeutics Inc) - Rasio kapitalisasi marang pendapatan|w2.cytomed.sg (GDTC) - Rasio rega marang pendapatan|CRIS (Curis) - Rasio rega marang pendapatan|APLM (Apollomics Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Inc (THAR)|Multiplikator P/S ADVB|Multiplikator P/S Genprex Inc (GNPX)|Rasio rega marang pendapatan Calidi Biotherapeutics, Inc. CLDI|SBFM: Rasio kapitalisasi marang pendapatan|Xenetic Bio - Multiplikator P/S|Salarius Pharmaceuticals Inc (SLRX) - Kapitalisasi marang pendapatan|PPBT: Multiplikator P/S|Rega marang dodolan American Oncology Network, Inc. (AONC)|Rasio rega marang pendapatan BeiGene, Ltd.|CKPT: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan ELEV (Elevation Oncology)|ICAD (icadmed.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S IKNA (Ikena Oncology)|NTBL - Kapitalisasi marang pendapatan|VIRX: Kapitalisasi marang pendapatan|MOR - Multiplikator P/S|NAYA Biosciences Inc. (NAYA) - Rasio rega marang pendapatan|Ascentage Pharma Group International - Rasio kapitalisasi pasar marang pendapatan
